Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
2023年7月20日 - 11:55PM
Press Release
Crossject signs
new licensing
agreement on ZENEO® Midazolam
epilepsy rescue therapy with AFT
Pharmaceuticals for Australia & New
Zealand
Exclusive licensing, distribution and promotion
agreement for ZENEO® Midazolam in epileptic seizures in Australia
and New Zealand
Pre-marketing payments of about €0.5m due to
Crossject from AFT
Dijon, France 20 July
2023 -- Crossject (ISIN:
FR0011716265; Euronext:
ALCJ), a specialty pharma company that develops and will
soon market a portfolio of drug device combinations for use in
emergency situations, announces the
signing of an Australia & New Zealand commercial agreement for
ZENEO® Midazolam, its innovative rescue treatment of epileptic
seizures.
‘‘We are pleased to expand our ongoing international roll-out of
ZENEO® Midazolam to treat certain epileptic crisis into Australia
and New Zealand, with this licensing agreement,” said
Patrick Alexandre, CEO of
Crossject. “AFT Pharmaceuticals
is a particularly well suited partner for us in Australasia because
of its strong presence in the region and extensive experience with
successful commercial launches. We look forward to collaborating to
ensure a strong launch for our exciting innovative needle-free
emergency treatment for epileptic crisis.’’
Intramuscular Midazolam is the gold standard to treat patients
in the case of certain epileptic seizures1 that represent a
life-threatening situation. The current solutions can be
challenging for non-healthcare-professionals to administer during
an emergency. There is a clear need for a simple and dependable
needle-free way to administer an emergency treatment for epilepsy.
The simplicity of use of ZENEO® (see “Intuitive” study2), will
afford patients and their caregivers a needle-free injection
technology that delivers life-saving medicine in less than 1/10th
second. “We are very pleased to partner with Crossject to bring
ZENEO® Midazolam to our core market,” said Dr Hartley
Atkinson, CEO of AFT Pharmaceuticals. ‘‘This
ground-breaking needle-free system for rapidly and easily
administering a life-saving drug to epileptic patients will fulfill
an existing need for the treatment of epileptic seizures.
Crossject’s ZENEO® technology represents a natural fit with our
longstanding commitment to innovation.” Under the terms of the
agreement, AFT will be responsible for all local regulatory and
commercial activities. In exchange for the commercial rights,
Crossject shall receive: about €0.5m (AUD 0.79m) of premarketing
payments from AFT. About €150k (AUD 237k) is due after the
signature of the agreement. The remainder consists of development
and approval milestones. Crossject will manufacture and sell the
product to AFT at a mid-double-digit percentage of AFT’s net
selling price to wholesalers, with a minimum floor price per unit.
Filing for marketing approval to Australia and New Zealand
regulatory authorities is expected a few months after filing in
Europe.
Epilepsy is the fourth most common neurological
disorder in the world, affecting roughly 1 in 26 people, according
to the Epilepsy Foundation. The disorder affects people of all
genders, races, ethnic backgrounds and ages. It causes surges of
electrical activity in the brain that can cause recurring
seizures.
Epilepsy afflicts an estimated 151,000 people in Australia3 and
an estimated 50,000 people in New Zealand4.
Crossject SA (Euronext:ALCJ;
www.crossject.com) is developing and will soon market a portfolio
of drugs for use in emergency situations (epilepsy, overdose,
allergic shock, severe migraine and asthma attack). With its
patented needle-free self-injection system, Crossject aims to
become the world leader in self-administered emergency medications.
The company has been listed on the Euronext Growth market in Paris
since 2014, and benefits from Bpifrance funding.
AFT Pharmaceuticals Limited (ASX: AFP &
NZX:AFT) is a specialty pharmaceutical company operating primarily
in Australasia, but with product distribution agreements worldwide.
The company's product portfolio includes prescription and
over-the-counter medicines to treat a range of conditions, as well
as a patented nebulizer.
For further information, please contact:
Crossject Patrick Alexandre Chief Executive
Officerinfo@crossject.com |
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
|
1 Pre-hospital midazolam for benzodiazepine-treated seizures
before and after the Rapid Anticonvulsant Medication Prior to
Arrival Trial: A national observational cohort study.2 Human
factors study of ZENEO® (needle-free autoinjector) and comparison
of different user instruction formats. 3 Epilepsy in Australia, how
many Australians have epilepsy? 4 Epilepsy consumer experience
survey 2018.
Crossject (EU:ALCJ)
過去 株価チャート
から 4 2024 まで 5 2024
Crossject (EU:ALCJ)
過去 株価チャート
から 5 2023 まで 5 2024